KEGG pathway analysis indicates that the selected miRNA panel can specifically target SMAD3/CDKN1A/MYC in the TGF-B/SMAD pathway to influence tumor suppression and oncogenesis, as well as target CASP3 in the P13K/AKT pathway to influence apoptosis. The gene discussed is CDKN1A; the disease is neoplasm.